Igal Kushnir's research while affiliated with Tel Aviv University and other places

Publications (4)

Article
Neoadjuvant chemotherapy for osteosarcoma is the standard of care, but there is still confusion regarding the best chemotherapy regimen and the optimal intensity. This retrospective study intends to evaluate whether there is a clear correlation between the chemotherapy dose intensity (DI) and the percentage of tumor necrosis, the risk of tumor recu...
Article
Full-text available
Until recently, metastatic melanoma was a disease with limited treatment options and a poor prognosis. Dacarbazine was accepted as the standard treatment for melanoma in the 1970s, and despite inducing an overall survival of approximately 7.4 months, it remained so until relatively recently. In the last few years, significant advances in the molecu...
Article
Glioblastoma multiforme (GBM) is an ultimately fatal disease that affects patients of all ages. Elderly patients (65 years and older) constitute a special subgroup of patients characterized by a worse prognosis and frequent comorbidities. To assess the efficacy of different treatment modalities in terms of survival in elderly patients with GBM. Usi...

Citations

... Primary LMS of the thyroid is a rare tumour and approximately only 30 cases have been reported previously. [3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18][19][20][21][22] The other common sites for LMS are gastrointestinal tract, retroperitoneum and pelvis. 23 According to the histological tumour classification by World Health Organization (WHO), thyroid LMS is classified as a member of the smooth-muscle tumours of thyroid gland. ...
... 14 Saeter et al. demonstrated that Huvos I patients had lower H24 and H48 methotrexate levels, 11 Delepine et al. adapted chemotherapy doses to the excretory potential of each patient 15 increasing thus the tumor necrosis, and Bacci identified the 700 mmol/l Methotrexate level to be linked to a higher complete tumor necrosis rate. 16 On the other hand, Eselgrim et al. did not found any statistical relation between 200 days dose-intensity of chemotherapy and survival outcome, nor did the European Osteosarcoma Intergroup or Kushnir et al. [17][18][19] These results suggest that patient prognosis is not threatened by inevitable treatments delays. Our patients received neoadjuvant chemotherapy in due time (median duration time of 12 weeks) and mostly accomplished all their scheduled cures (median number of 7 + 2 cures for methotrexate-treated patients and 3 + 1 for Adriamycin-Cisplatinum-Ifosfamide-treated patients). ...
... The specialist needs to provide the GP with clear and practical information for optimal followup care. 1 BRAF V600 inhibitors have led to significant improvement in survival of patients with metastatic melanoma with BRAF V600 mutation. [2][3][4][5][6] We evaluated the information on vemurafenib transmitted from oncodermatologist to GP in our region. ...
... In Table 10, a list of the main studies on elderly GBM patients that have been published from the introduction of Stupp regimen (2005) is reported, with a particular focus on patient and tumour characteristics, post-surgical complications, treatment modalities, and outcome [19][20][21][22][23][24][25][26][27][28][29][30][31][32][33]. As compared to other studies, we could identify the presence of different subgroups of patients with different outcomes according to clinical and molecular characteristics (i.e., MGMTp status), extent of resection, and adjuvant radio-chemotherapy. ...